REHOVOT, Israel – November 05, 2026 -- Evogene Ltd. (Nasdaq: EVGN; TASE: EVGN) will release its third-quarter 2026 financial results on Thursday, November 19, 2026, the computational chemistry company announced.
Management will host a conference call the same day at 9:00 AM Eastern Time (4:00 PM Israel time) to discuss the results. Attendance via Zoom requires advance registration.
Evogene will publish a full conference recording on its website a few days after the call
The company plans to make the entire conference available online shortly after the event, giving investors who miss the live session access to management's commentary.
Evogene builds its pipeline on the ChemPass AI generative design platform
Evogene specializes in the generative design of small molecules for the pharmaceutical and agricultural industries. Its proprietary generative AI, ChemPass AI, explores vast chemical space to generate novel, highly potent small molecules optimized across multiple critical parameters.
The company pursues product development through strategic partnerships alongside internal programs, targeting drug development and ag chemical products. The announcement contained no financial figures or guidance ahead of the November 19 release.